The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β 2-agonist (LABA), as ...
In a recent article published in the New England Journal of Medicine, researchers presented the findings of an ongoing double-blinded, randomized, placebo-controlled platform-protocol clinical trial, ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA -- 12/06/13 -- GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback